Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities researchers at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX – Get Rating) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, Alliance Global Partners initiated coverage on Athersys in a research note on Monday, March 6th. They issued a “buy” rating […]
/PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around...
The Cleveland-based cell therapy and regenerative medicine company said it has secured a patent for a system known as the Secure Integrated Freezer Unit and is looking for a partner to commercialize it.
Data Bridge Market Research analyses that the stem cell therapy market, which is USD 257 million in 2022, is expected to reach USD 921.12 million by 2030,...
The Type B meeting with the U.S. Food and Drug Administration is scheduled for late March. The Cleveland-based cell therapy and regenerative medicine company said it 'intends to discuss proposed modifications' to the Phase 3 MASTERS-2 clinical for MultiStem, an experimental therapy targeted at ischemic stroke.